Welcome to PsychiatryAI.com: [PubMed] - Psychiatry AI Latest

Diagnostic performance of non-invasive liver fibrosis risk scores in biopsy-proven non-alcoholic fatty liver disease patients in India

Evidence

Indian J Gastroenterol. 2023 May 16. doi: 10.1007/s12664-022-01335-3. Online ahead of print.

ABSTRACT

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide. India and other developing countries are witnessing an unprecedented rise in the prevalence of NAFLD. As part of population-level strategy, at primary healthcare, an efficient risk stratification is crucial to ensure appropriate and timely referral of individuals who require care at secondary and tertiary levels. The present study was conducted to assess the diagnostic performance of two non-invasive risk scores, fibrosis-4 (FIB-4), and NAFLD fibrosis score (NFS), in Indian patients of biopsy-proven NAFLD.

METHODS: We conducted a retrospective analysis of biopsy-proven NAFLD patients that reported to our center between 2009 and 2015. Clinical and laboratory data were collected and two non-invasive fibrosis scores, NFS and FIB-4 score, were calculated using the original formulas. Liver biopsy was utilized as gold standard for diagnosis of NAFLD, diagnostic performance was determined by plotting receiver operator characteristic (ROC) curves and area under the ROC curve (AUROC) was calculated for each score.

RESULTS: The mean age of 272 patients included was 40 (11.85) years and 187 (79.24%) were men. We found that the AUROCs for FIB-4 score (0.634) was higher for any degree of fibrosis as compared to NFS (0.566). The AUROC for FIB-4 for advanced liver fibrosis was 0.640 (.550-.730). The performance of the scores for advanced liver fibrosis was comparable with overlapping confidence intervals for both scores.

CONCLUSION: The present study found an average performance of FIB-4 and NFS risk scores for detecting advanced liver fibrosis in Indian population. This study highlights the need for devising novel context-specific risk scores for efficient risk stratification of NAFLD patients in India.

PMID:37191918 | DOI:10.1007/s12664-022-01335-3

Document this CPD Copy URL Button

Google

Google Keep Add to Google Keep

LinkedIn Share Share on Linkedin Share on Linkedin

Estimated reading time: 5 minute(s)

Latest: Psychiatryai.com #RAISR4D

Cool Evidence: Engaging Young People and Students in Real-World Evidence ☀️

Real-Time Evidence Search [Psychiatry]

AI Research [Andisearch.com]

Diagnostic performance of non-invasive liver fibrosis risk scores in biopsy-proven non-alcoholic fatty liver disease patients in India

Copy WordPress Title

🌐 90 Days

Evidence Blueprint

Diagnostic performance of non-invasive liver fibrosis risk scores in biopsy-proven non-alcoholic fatty liver disease patients in India

QR Code

☊ AI-Driven Related Evidence Nodes

(recent articles with at least 5 words in title)

More Evidence

Diagnostic performance of non-invasive liver fibrosis risk scores in biopsy-proven non-alcoholic fatty liver disease patients in India

🌐 365 Days

Floating Tab
close chatgpt icon
ChatGPT

Enter your request.

Psychiatry AI RAISR 4D System Psychiatry + Mental Health